Pathways to Alzheimer's disease

• Autores: J. Hardy, N. Bogdanovic, B. Winblad, E. Portelius, Nancy C. Andreasen, A. Cedazo-Minguez, Henrik Zetterberg
• Localización: Journal of Internal Medicine, ISSN-e 1365-2796, Vol. 275, Nº. 3, 2014, págs. 296-303
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Recent trials of anti-amyloid agents have not produced convincing improvements in clinical outcome in Alzheimer's disease; however, the reason for these poor or inconclusive results remains unclear. Recent genetic data continue to support the amyloid hypothesis of Alzheimer's disease with protective variants being found in the amyloid gene and both common low-risk and rare high-risk variants for disease being discovered in genes that are part of the amyloid response pathways. These data support the view that genetic variability in how the brain responds to amyloid deposition is a potential therapeutic target for the disease, and are consistent with the notion that anti-amyloid therapies should be initiated early in the disease process.